OptiNose, Inc. (OPTN)
After hours:
| Previous close | 1.6800 |
| Open | 1.6800 |
| Bid | 1.7900 x 900 |
| Ask | 1.8700 x 800 |
| Day's range | 1.6800 - 1.8400 |
| 52-week range | 1.5500 - 4.3000 |
| Volume | |
| Avg. volume | 155,621 |
| Market cap | 205.73M |
| Beta (5Y monthly) | -0.27 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.8400 |
| Earnings date | 10 May 2023 - 15 May 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 4.17 |
- Simply Wall St.
We're Not Very Worried About OptiNose's (NASDAQ:OPTN) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
- Zacks
OptiNose (OPTN) Reports Q4 Loss, Tops Revenue Estimates
OptiNose (OPTN) delivered earnings and revenue surprises of -6.25% and 3.12%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
Optinose Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Operational Highlights
Company reports fourth quarter and full year 2022 XHANCE net revenue of $20.9 million and $76.3 million Company submitted sNDA for XHANCE label expansion in February 2023 Physicians diagnose chronic sinusitis 10 times more frequently than XHANCE’s current nasal polyps indication and there is no FDA-approved medication for these patients Conference call and webcast to be held today at 8:00 a.m. Eastern Time YARDLEY, Pa., March 07, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical
